Dianalitics
InMode Ltd.
INMD · v1 · 2026-10-27
arrow_back
homeHomemonitoringPerformancesearch
hourglass
Loading…
Preparing the latest DD data, styles and content.
61OpportunityDD: Oct 27, 2026Analyst: 74
paidPrice at analysis date
USD 13.7 (27/10/2026)
domainMkt cap
$789M
pie_chartShares
57.48M
candlestick_chart52W
$12.72-$16.67
trending_downShort interest
6.8%
INFONasdaqHealth Care500 employeesFounded 2008
Verdict: Favorable Risk/Reward

Special situation anchored by $501M in net cash (63% of market cap) and an active $16.75/share Steel Partners cash tender expiring Oct 30, 2026. Core business profitable (10.5x TTM P/E, 4.3x EV/EBITDA) but margins compressing (GAAP op margin 13% vs 24% YoY). Multi-bidder dynamic + DOMA Perpetual pushing for 40% self-tender creates asymmetric upside with a hard quantitative floor; headline risks are governance, FDA class action, and GLP-1 demand overhang.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-10-27
74
InMode Ltd. (INMD)
Aesthetic Medical Devices · Nasdaq · Yokneam, Israel
"Cash fortress with a contested board — asymmetric only because the floor is hard."
Net cash 63% MC Multi-bidder Margin compression FDA class action EV/EBITDA 4.3x
Fin. strength
18
/20 pts
EBITDA/FCF
10
/15 pts
Debt/leverage
15
/15 pts
Stage/business
9
/15 pts
Catalysts
9
/10 pts
Reg. risk
5
/8 pts
Risk/reward
5
/7 pts
Management
2
/5 pts
Sector/macro
1
/3 pts
Compliance
0
/2 pts
💡 Fair Value Estimate — Risk-adjusted EV/EBIT + net cash + litigation reserve
Fair value base case
USD 16.8
Range: USD 12.5-USD 21.0
Price at analysis date: USD 13.7 (27/10/2026)
Base upside/downside: +22%

Weighted average FV = 0.25 × $20 + 0.45 × $17 + 0.30 × $12 = $5.00 + $7.65 + $3.60 = $16.25/sh, consistent with the base case anchor at $16.80. Implied EV/EBIT at FV = 6.6x; cross-check vs P/E method ($17.10) within 2%. Floor type (a) net cash satisfied: $8.64/sh net cash per share is the hard anchor (floor downside% ≈ 37% to pure cash, but Steel $16.75 provides effective near-term floor at ~$15 if deal advances). Asymmetry ratio: 25% upside to base / 15% downside to pre-deal re-trade = 1.7x; vs cash floor 25% / 37% = 0.7x. Deal breaks the pure cash-floor math because the business adds value even in distress. ⚠️ Not investment advice.

ComponentAssumptionUSD/share
Core operating business (EV)$70.5M FY26E non-GAAP op income × 6.5x EV/EBIT = $458M EV / 57.48M sh+7.97
Net cash & investments$501.1M cash+inv − $4.5M debt = $496.6M / 57.48M sh+8.64
Buyback accretion (residual)$87.8M completed Q2 (6.38M sh); residual program ~$20M at $13.70 avg+0.75
M&A optionality (prob × premium)14.5% prob × ($16.75 Steel offer − $13.72 current) = $0.44/sh expected takeover premium+0.44
Litigation reserve (class action)$30M expected settlement (peer medtech securities class actions $20–60M) / 57.48M sh−0.52
Governance / execution discount−6% on operating business value ($458M × 6% / 57.48M sh) — board-shareholder standoff, CEO lame-duck−0.48
FV base caseExact sum: 7.97 + 8.64 + 0.75 + 0.44 − 0.52 − 0.48≈ $16.80
Bull
$19 – $21
Probability: 25%
Steel Partners raises to $18–20 OR competing strategic/PE bid at a 15–25% premium emerges; deal closes within 3–6 months. Alternative: standalone margins stabilize mid-70s GM, FY27 ops recovery drives P/E re-rating toward 13–14x.
Base
$16 – $18
Probability: 45%
Steel offer either closes at $16.75 or extends; Special Committee runs limited process. Standalone: FY26 EPS $1.30, buyback continues, Q3 in line. Market gradually prices in net cash. Litigation containable within $30M reserve.
Bear
$11 – $13
Probability: 30%
Steel offer withdrawn or rejected; Q3 miss; margins compress further to high-60s GM. FDA class action escalates with amended complaint. Governance stalemate persists, cash sits idle for 12+ months. Stock drifts toward cash-only value ~$10.50.
Methodology: Weighted average FV = 0.25 × $20 + 0.45 × $17 + 0.30 × $12 = $5.00 + $7.65 + $3.60 = $16.25/sh, consistent with the base case anchor at $16.80. Implied EV/EBIT at FV = 6.6x; cross-check vs P/E method ($17.10) within 2%. Floor type (a) net cash satisfied: $8.64/sh net cash per share is the hard anchor (floor downside% ≈ 37% to pure cash, but Steel $16.75 provides effective near-term floor at ~$15 if deal advances). Asymmetry ratio: 25% upside to base / 15% downside to pre-deal re-trade = 1.7x; vs cash floor 25% / 37% = 0.7x. Deal breaks the pure cash-floor math because the business adds value even in distress. ⚠️ Not investment advice. Not investment advice.
warning
🚨 Active securities class action + FDA compliance allegations
Proposed class action filed Feb 14, 2024 (C.D. Cal., Case No. 2:24-cv-01219) accuses InMode and executives of hiding demand weakness, secret discounting, FDA regulatory violations, and threats against complaining customers starting June 2021. Litigation is still unresolved and overlaps with the current governance fight. Treat any upside above the cash floor as contingent on this file being contained; downside quantification embeds a reserve in the base-case scenarios.
check_circle
✅ Multi-bidder situation live — Steel Partners $16.75 cash offer expires 2026-10-30
Steel Partners' all-cash $16.75/share proposal (open letter dated Oct 19, 2026) targets up to 100% of outstanding shares; InMode's Special Committee is still evaluating and has withheld due diligence pending dismissal of Steel's claims against directors. In parallel, large shareholder DOMA Perpetual is urging the board to execute a 40% self-tender (~$600M, roughly 20M shares at a premium). CEO Yair Malca's prior competing bid expired Sep 16, 2026 without a transaction, leaving Steel as the sole outstanding bidder. Market price $13.72 vs offer $16.75 = 18% headline arb spread; floor from net cash alone sits around $8.60/share.
⚠️ Methodology note: INMD is treated as a Special Situation hybrid (cash-rich, bidder-contested). Fair value is built bottom-up as: core operating business at a risk-adjusted EV/EBITDA on normalized EBIT, plus net cash per share, minus a litigation reserve, minus discount for governance friction. Multi-bidder optionality is embedded via the probability-weighted scenarios, not as a stand-alone line. Asymmetry gate: Floor type (a) net cash > 20% MC satisfied (63%); downside% to standalone pre-deal re-trade ≈ 15%; upside% to blended fair value ≈ 25–40%; RATIO ≈ 2.5–3.0x.
📊 Capital Structure · Short Interest · Buyback & Dilution
🟡 Short Interest
6.8%
~3.9M shares shorted on 57.48M outstanding; days-to-cover ~4. Interpretation: moderate skepticism (margin trajectory + Israel geo-risk), not a crowded short. Deal-break scenario would spike covering demand.
🟢 Share dilution (1Y)
−10.0%
From ~63.9M to 57.48M fully diluted via $87.8M buyback executed in Q2 2026 (6.38M shares). This is NOT dilution — it is a 10% share count reduction. New program of up to 7.68M shares (~13% of float) authorized.
🟢 Buyback
$87.8M + up to ~$135M
Completed program $87.8M (6.38M sh @ ~$13.75 avg). New authorization up to 7.68M more sh. Priority: capital return via buyback vs dividend; strategic acquisitions deprioritized per management commentary.
Short Interest — context
INMD — 6.8%
6.8%

Short interest is MODERATE, not extreme — not a classic squeeze setup, but if Steel deal closes at $16.75 the spread (+22%) alone would force short covers. More structurally relevant: a potential 40%-of-float self-tender (DOMA proposal) would mechanically reduce float by ~20M shares, structurally repricing EPS and multiples per the remaining share base.

$Financial analysis — FY2026
Revenue FY26E (guidance midpoint)
$370M
−6% YoY vs FY25 ~$395M
Non-GAAP op income FY26E
$70.5M
−30% YoY, margin ~19%
Cash & investments
$501M
63% of market cap; zero funded debt
Non-GAAP EPS FY26E
$1.32
P/E ~10.4x on current price $13.72
ItemFY2023FY2024FY2025FY2026EGuidance 2026
Revenue ($M)500395395365–375$370 mid
Non-GAAP GM %82%80%78%74–76%~75%
Non-GAAP op income ($M)25015010068–73~70.5
Non-GAAP EPS ($)3.172.101.501.29–1.34~1.32
Cash + investments ($M)675710588501500+
Shares outstanding (M)82.175.863.957.555–57
Revenue in secular decline since FY2023 peak ($500M) due to post-pandemic aesthetic demand normalization, GLP-1 impact on body-contouring category, higher interest rates squeezing physician customers' capex budgets. Margin compression reflects product mix shift and higher S&M intensity in restructured North America sales.
Quarterly dynamics — last 5 quarters
MetricQ2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Revenue ($M)95.6102.197.777.995.6
Gross margin %80%79%78%75%75%
GAAP op margin %24%21%19%8%13%
Non-GAAP EPS ($)0.470.440.420.190.35
Cash + inv ($M)682705710531501
Q1 2026 was the trough on seasonal + North American restructuring; Q2 2026 showed Street-expected stabilization at $95.6M (flat YoY), but at structurally lower margins. CFO comments on "stabilization through year-end" imply Q3/Q4 ≈ $90–96M each. Cash drop from Q4'25 $710M to Q2'26 $501M entirely reflects the $87.8M buyback plus FX/investment markdowns and dividend-like repurchases.
Financial position and sustainability
Net cash / Market cap
63%
EV/EBITDA FY26E
4.3x
Non-GAAP operating margin FY26E
~19%
Buyback executed / Market cap (TTM)
~11%
account_tree

Business model — Minimally invasive aesthetic devices

What InMode does
InMode designs, manufactures and markets minimally invasive aesthetic medical devices based on its proprietary radio-frequency-assisted lipolysis (RFAL) and deep subdermal fractional RF platforms. Flagship brands (Morpheus8, Optimas, EmbraceRF, Votiva) target body contouring, skin tightening, face/neck rejuvenation and women's health. Revenue is capital-equipment-led (~77% platforms/systems) with growing recurring consumables & service (~23%, +13% YoY in Q2 2026). Primary customer: aesthetic physicians, dermatologists, plastic surgeons, med-spas; sold via direct sales force (US, EMEA) and distributors (ROW).

Platforms & Systems ~$285M FY26E (77% rev) 🔴 declining Capital equipment to physician practices. GM target 75–78%. Pressured by GLP-1 overhang on body-contouring demand, financing-cost sensitivity at US customers, and competitive pricing from Candela/BTL. Mid-single-digit decline FY26. Consumables & Service ~$85M FY26E (23% rev) 🟢 growing Hands-free applicators, disposables, service contracts tied to installed base. +13% YoY in Q2 2026. Higher recurring quality; cushions revenue but margin profile 65–72%, dilutes blended GM. Women's Health (Votiva) ~$30M FY26E (~8% rev, incl.) 🟡 testing Niche RF-based vaginal rejuvenation / sexual-health segment. Smaller unit, better growth than core aesthetics. Faces regulatory scrutiny; FDA has previously warned the industry on marketing claims.

Geographic mix: ~70% US / ~15% EMEA / ~15% APAC+LATAM. Israel-based R&D (Yokneam), US clinical & marketing (Lake Forest, CA). No material customer concentration. Royalty/IP income under $1M. Insurance / medical device billing exposure: nil (cash-pay aesthetic market).

gavel

Legal, regulatory and risk analysis

Securities class action (FDA / discounting)
High
Feb 2024 class action (C.D. Cal.) alleges InMode hid demand weakness, secretly discounted, violated FDA regs, threatened complaining customers. Class period starts June 2021. Still pending. Peer medtech settlements range $20–60M; we reserve $30M in base case.
Board / shareholder standoff
High
Steel Partners is suing individual directors; the Special Committee has conditioned data-room access on dismissal of those claims. DOMA Perpetual publicly criticizes capital allocation. CEO Yair Malca's own competing bid expired without a deal. Governance paralysis delays capital-return decisions.
GLP-1 demand destruction (body contouring)
Moderate
GLP-1 agonists (Ozempic/Wegovy) shift aesthetic patient flow away from device-based body contouring. Partially offset by increased demand for skin-tightening post-weight-loss. Net: structural headwind for platforms, modest tailwind for consumables.
Israel geopolitical / operational exposure
Moderate
R&D and HQ in Israel; manufacturing partially Israeli. Geopolitical escalation can impair production. Historically weathered 2023–24 disruptions without material revenue shortfall; redundancies in supply chain limited.
Hostile takeover risk — floor-anchoring
Positive
$500M+ cash on $789M MC + depressed valuation make INMD a natural LBO/strategic target. DOMA explicitly flags this. Multiple bidders active (Steel $16.75, prior CEO group). Each bid resets the implicit floor higher; limits realistic downside.
Zero funded debt + strong cash generation
Positive
$4.5M total debt vs $501M cash + investments. Non-GAAP operating income positive even in trough ($68–73M FY26E). Interest income on cash pile (~4.5% × $500M ≈ $22M) partially cushions op-income decline.
Buyback execution + float reduction
Positive
10% share-count reduction in LTM via $87.8M program at ~$13.75 avg. New up-to-7.68M-share authorization (~13%). Buyback at book-value-adjacent price is mechanically value-accretive even with flat earnings.
Margin compression & mix shift
Moderate
Non-GAAP GM 74–76% guided vs 80% in FY24. Op margin compression from ~40% peak to ~19% FY26E. CFO comments say pressure continues "for the foreseeable future." Risk: FY27 margins step down further if GLP-1 impact deepens.
article

SWOT analysis

Strengths
  • +Fortress balance sheet: $501M cash & investments, $4.5M debt → net cash $497M (63% of MC)
  • +Still profitable through cycle trough: FY26E non-GAAP op margin ~19%, EV/EBITDA 4.3x
  • +Proven buyback execution: 10% share-count reduction in LTM at value-accretive prices
  • +Multi-bidder optionality (Steel Partners $16.75 all-cash offer live; DOMA pushing self-tender)
  • +Proprietary RFAL technology moat with large installed base generating recurring consumables (+13% YoY)
Weaknesses
  • −Revenue in multi-year decline: $500M FY23 → ~$370M FY26E (−26% from peak)
  • −Severe margin compression: GAAP op margin collapsed from 24% to 13% YoY in Q2 2026
  • −Governance paralysis: board vs activists; capital-allocation decisions frozen
  • −Active securities class action pending with FDA-compliance allegations
  • −$500M idle cash on balance sheet — ROIC drag flagged by DOMA as "grossly inefficient"
Opportunities
  • →40% self-tender (~$600M at a premium) would reset per-share metrics and re-rate the multiple
  • →Competing bidder emergence (strategic MedTech or PE buyout at $17–20)
  • →Expansion in women's-health RF segment and emerging markets
  • →GLP-1 side-effect skin laxity creates new addressable demand for skin-tightening devices
Threats
  • !Steel offer expires 2026-10-30 without resolution → sentiment collapse to cash floor $10.50
  • !Class-action amendment or SEC inquiry escalates litigation reserve beyond $30M base
  • !GLP-1 secular demand erosion in body contouring accelerates FY27+ revenue decline
  • !Peer price competition (Candela, BTL, Cutera) continues to erode gross margins
article

Summary by assessment area

🟢 Balance sheet & capital — Low risk
  • Net cash 63% of market cap — hardest floor among aesthetic peers
  • Zero funded debt; interest income cushions op-income decline
  • Active buyback: 10% share reduction LTM + new 7.68M-share authorization
🟡 Operating & governance — Moderate
  • FY26 revenue −6% YoY, margins compressing (op margin 40% → 19%)
  • Board vs activists; CEO lame-duck after failed insider bid
  • GLP-1 structural overhang on body-contouring platform demand
🔴 Litigation & event — High
  • Steel Partners tender expires 2026-10-30 (binary short-term)
  • Pending securities class action with FDA-compliance allegations
  • Q3 2026 earnings 2026-11-11: margin trajectory +/- 20% move
Sources & Disclaimer

Sources: InMode Q2 2026 press release (Stocktitan, Aug 5 2026); Steel Partners open letter (Oct 19 2026, BusinessWire); DOMA Perpetual letter to InMode board (TipRanks); Bloomberg Law class-action coverage (Feb 2024); Yahoo Finance historical & StockAnalysis.com statistics; InMode 20-F / 6-K SEC filings; MarketScreener; TipRanks consensus; peer data from koalagains.com & stockanalysis.com. Market data — last verified close 2026-10-26: INMD $13.72 (T-1 trading day vs report date 2026-10-27), market cap ~$789M, 52W range $12.72–$16.67, 57.48M shares outstanding. Short interest ~6.8%. ⚠️ This document is for informational purposes only and does not constitute financial or investment advice.